

Rowan University

## Rowan Digital Works

---

Rowan-Virtua Research Day

26th Annual Research Day

---

May 5th, 12:00 AM

# Comparing the Relapse Rate Between Medication Assisted-only Treatment and Medication-Assisted Treatment with an Osteopathic Manipulative Treatment Regimen in Patients with Musculoskeletal Pain

Karen Huang  
*Rowan University*

Danielle Cooley  
*Rowan University*

Follow this and additional works at: [https://rdw.rowan.edu/stratford\\_research\\_day](https://rdw.rowan.edu/stratford_research_day)



Part of the [Alternative and Complementary Medicine Commons](#), [Musculoskeletal System Commons](#), [Osteopathic Medicine and Osteopathy Commons](#), [Pathological Conditions, Signs and Symptoms Commons](#), and the [Substance Abuse and Addiction Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

---

Huang, Karen and Cooley, Danielle, "Comparing the Relapse Rate Between Medication Assisted-only Treatment and Medication-Assisted Treatment with an Osteopathic Manipulative Treatment Regimen in Patients with Musculoskeletal Pain" (2022). *Rowan-Virtua Research Day*. 52.  
[https://rdw.rowan.edu/stratford\\_research\\_day/2022/May5/52](https://rdw.rowan.edu/stratford_research_day/2022/May5/52)

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.




## Comparing the Relapse Rate Between Medication Assisted-only Treatment and Medication-Assisted Treatment with an Osteopathic Manipulative Treatment Regimen in Patients with Musculoskeletal Pain

Karen Huang, Danielle Cooley, DO  
Rowan Medicine NeuroMusculoskeletal Institute

### Introduction

Since the opioid crisis first began in 1991, opioid-related overdoses in the United States have continued to increase dramatically, killing nearly 47,000 people in 2018, and making it one of the most pressing issues in healthcare.<sup>1</sup> The most reported reason for misuse of pain relievers was to relieve physical pain.<sup>2</sup> The increase in opioid abuse has also led to an increase in patients seeking medication-assisted treatment (MAT).

Osteopathic manipulative treatment (OMT) has been shown to have efficacy in relieving both chronic and acute pain.<sup>3,4,5</sup> No current studies have investigated the use of OMT as an adjunct treatment to MAT for patients with musculoskeletal pain and opioid dependence.



### Objectives

This study aims to evaluate the benefits of OMT in patients diagnosed with musculoskeletal pain who are seeking MAT with Buprenorphine for opioid abuse. We hypothesize that using additional OMT to treat the physical pain that underlies opioid use will reduce relapse rates in patients receiving MAT alone.

### Methods

We are employing a Randomized Controlled Trial (RCT) to compare the number of relapses over a 90-day course between patients receiving OMT + MAT versus patients receiving only MAT. After randomly placing patients into either the control (MAT only) or treatment group (OMT + MAT), all patients will follow same 12-week schedule, with patients in the treatment group also receiving additional OMT with each visit.

### Expected Outcomes

We are currently in the data collection phase of our research; however, we anticipate that our study will show lower relapse in the treatment group compared to the control group.

Week	Visit Day	Medication Plan	Treatment Plan
1	Day 1: Initial visit and evaluation	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation.</li></ul> If in withdrawal, try to get approval for buprenorphine product and initiate treatment (this may take up to 24 hours for prior authorization or the medication to occur)	<ul style="list-style-type: none"><li>• If medication approved, follow up in one week.</li><li>• If medication not approved or patient not in withdrawal, follow up the next day</li></ul>
	Day 2- Supervise induction	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation</li><li>• Rx for Buprenorphine product and initiate treatment</li></ul>	<ul style="list-style-type: none"><li>• New Rx for Buprenorphine product given</li><li>• Follow up appointment in 1 week</li></ul>
2	1-week follow-up visit	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation</li><li>• Rx for Buprenorphine product and initiate treatment</li></ul>	<ul style="list-style-type: none"><li>• If rapid UDS is negative, new Rx or Buprenorphine product given and follow up appointment in 2 weeks</li><li>• If rapid UDS is positive*, new Rx for Buprenorphine product given and follow up appointment in 1 week</li></ul>
4	2-week follow-up visit	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation</li><li>• Rx for Buprenorphine product and initiate treatment</li></ul>	<ul style="list-style-type: none"><li>• If rapid UDS is negative, new Rx or Buprenorphine product given and follow up appointment in 2 weeks</li><li>• If rapid UDS is positive, new Rx for Buprenorphine product given and follow up appointment in 1 week</li></ul>
8	4-week follow-up visit	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation</li><li>• Rx for Buprenorphine product and initiate treatment</li></ul>	<ul style="list-style-type: none"><li>• If rapid UDS is negative, new Rx or Buprenorphine product given and follow up appointment in 2 weeks</li><li>• If rapid UDS is positive*, new Rx for Buprenorphine product given and follow up appointment in 1 week</li></ul>
12	4-week follow-up visit	<ul style="list-style-type: none"><li>• Rapid UDS and send out for confirmation</li><li>• Rx for Buprenorphine product and initiate treatment</li></ul>	<ul style="list-style-type: none"><li>• If rapid UDS is negative, new Rx or Buprenorphine product given and follow up appointment in 2 weeks</li><li>• If rapid UDS is positive*, new Rx for Buprenorphine product given and follow up appointment in 1 week</li></ul>
16 and beyond	(beyond scope of this study): patients will continue with 4-week follow-ups indefinitely		

**If at any point in the study period, UDS is positive, patient will revert to weekly visits until UDS is negative. Once negative, patient will have 2-week and then 4-week follow-ups.**